The estimated Net Worth of Robert W. Hesslein is at least $6.51 million dollars as of 20 March 2023. Mr. Hesslein owns over 4,410 units of Voyager Therapeutics Inc stock worth over $641,816 and over the last 8 years he sold VYGR stock worth over $2,627,612. In addition, he makes $3,240,960 as Senior Vice President et General Counsel at Voyager Therapeutics Inc.
Robert has made over 25 trades of the Voyager Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 4,410 units of VYGR stock worth $34,222 on 20 March 2023.
The largest trade he's ever made was selling 18,021 units of Voyager Therapeutics Inc stock on 16 January 2018 worth over $1,158,750. On average, Robert trades about 3,278 units every 77 days since 2016. As of 20 March 2023 he still owns at least 102,200 units of Voyager Therapeutics Inc stock.
You can see the complete history of Mr. Hesslein stock trades at the bottom of the page.
Robert W. Hesslein is Senior Vice President, General Counsel of the Company since April 2019. Mr. Hesslein was previously the Senior Vice President, General Counsel, and Chief Compliance Officer at Foundation Medicine, Inc., a molecular information company focused on cancer genomics, which is now a subsidiary of Roche, from May 2012 to March 2019. Mr. Hesslein was previously Senior Vice President and Deputy General Counsel at Genzyme, a biotechnology company, which is now a subsidiary of Sanofi, from July 1996 to May 2012. Before Genzyme, from September 1990 to June 1996, Mr. Hesslein was a Second Vice President and Counsel at The New England, a mutual life insurance company. From September 1978 to August 1990, Mr. Hesslein was an associate and subsequently a partner at Csaplar & Bok, a Boston law firm. Mr. Hesslein earned his B.A. from Yale University and his J.D. from The Cornell Law School.
As the Senior Vice President et General Counsel of Voyager Therapeutics Inc, the total compensation of Robert Hesslein at Voyager Therapeutics Inc is $3,240,960. There are 1 executives at Voyager Therapeutics Inc getting paid more, with Omar Khwaja having the highest compensation of $3,815,770.
Robert Hesslein is 67, he's been the Senior Vice President et General Counsel of Voyager Therapeutics Inc since 2019. There are 2 older and 13 younger executives at Voyager Therapeutics Inc. The oldest executive at Voyager Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the Exec. Science Advisor & Director.
Robert's mailing address filed with the SEC is C/O VOYAGER THERAPEUTICS, INC.,, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Voyager Therapeutics Inc have traded over $22,599,571 worth of Voyager Therapeutics Inc stock and bought 9,198,716 units worth $93,782,260 . The most active insiders traders include Sanofi, Capital, Llc Eco R1 et Biosciences Inc Neurocrine. On average, Voyager Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $966,976. The most recent stock trade was executed by Robin Swartz on 2 April 2024, trading 1,357 units of VYGR stock currently worth $13,407.
voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.
Voyager Therapeutics Inc executives and other stock owners filed with the SEC include: